A Peroxisome Proliferator-Activated Receptor γ Ligand Inhibits Adipocyte Differentiation

The peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that regulate glucose and lipid homeostasis. The PPARγ subtype plays a central role in the regulation of adipogenesis and is the molecular target for the 2,4-thiazolidinedione class of antidiabetic drugs. Structura...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 96; no. 11; pp. 6102 - 6106
Main Authors Oberfield, Jennifer L., Collins, Jon L., Holmes, Christopher P., Goreham, Donna M., Cooper, Joel P., Cobb, Jeffery E., Lenhard, James M., Hull-Ryde, Emily A., Mohr, Christopher P., Blanchard, Steven G., Parks, Derek J., Moore, Linda B., Lehmann, Jürgen M., Plunket, Kelli, Miller, Ann B., Milburn, Michael V., Kliewer, Steven A., Willson, Timothy M.
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences of the United States of America 25.05.1999
National Acad Sciences
The National Academy of Sciences
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that regulate glucose and lipid homeostasis. The PPARγ subtype plays a central role in the regulation of adipogenesis and is the molecular target for the 2,4-thiazolidinedione class of antidiabetic drugs. Structural studies have revealed that agonist ligands activate the PPARs through direct interactions with the C-terminal region of the ligand-binding domain, which includes the activation function 2 helix. GW0072 was identified as a high-affinity PPARγ ligand that was a weak partial agonist of PPARγ transactivation. X-ray crystallography revealed that GW0072 occupied the ligand-binding pocket by using different epitopes than the known PPAR agonists and did not interact with the activation function 2 helix. In cell culture, GW0072 was a potent antagonist of adipocyte differentiation. These results establish an approach to the design of PPAR ligands with modified biological activities.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
To whom reprint requests should be addressed at: Glaxo Wellcome, NTH-M1421, 5 Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398. e-mail: tmw20653@glaxowellcome.com.
Communicated by Michael G. Rosenfeld, University of California, San Diego, La Jolla, CA
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.96.11.6102